A study of oxidative stress, cytokines and glutamate in Wilson disease and their asymptomatic siblings

Journal of Neuroimmunology

Volumn 274, Issue 1-2, 2014, Pages 141-148

  Kalita, Jayantee ^a   Kumar, Vijay ^a   Misra, Usha K ^a   Ranjan, Abhay ^a   Khan, Hamidullah ^b   Konwar, Rituraj ^b  

^a SANJAY GANDHI POSTGRADUATE INSTITUTE OF MEDICAL SCIENCES   (India)

^b CENTRAL DRUG RESEARCH INSTITUTE   (India)

Author keywords

Copper; Cytokine; Glutamate; Glutathione; Lipid peroxidation; Wilson disease

Indexed keywords

ANTIOXIDANT; CERULOPLASMIN; COPPER; CYTOKINE; GLUTAMIC ACID; GLUTATHIONE; INTERLEUKIN 10; INTERLEUKIN 6; INTERLEUKIN 8; MALONALDEHYDE; TROLOX C; TUMOR NECROSIS FACTOR ALPHA;

ADOLESCENT; ARTICLE; ASYMPTOMATIC DISEASE; CERULOPLASMIN BLOOD LEVEL; CLINICAL ARTICLE; CONTROLLED STUDY; COPPER BLOOD LEVEL; DISEASE DURATION; DISEASE SEVERITY; FEMALE; FLUOROMETRY; HUMAN; LABORATORY TEST; MALE; MEDICAL HISTORY; NEUROLOGIC DISEASE; NUCLEAR MAGNETIC RESONANCE IMAGING; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN ANALYSIS; SIBLING; SPECTROPHOTOMETRY; SYMPTOMATOLOGY; URINE LEVEL; WILSON DISEASE;

COPPER; CYTOKINE; GLUTAMATE; GLUTATHIONE; LIPID PEROXIDATION; WILSON DISEASE;

ADOLESCENT; ANTIOXIDANTS; CHILD; COPPER; CYTOKINES; FEMALE; GLUTAMIC ACID; GLUTATHIONE; HEPATOLENTICULAR DEGENERATION; HUMANS; INTERLEUKIN-10; INTERLEUKIN-6; INTERLEUKIN-8; LIPID PEROXIDATION; MALE; OXIDATIVE STRESS; SIBLINGS; TUMOR NECROSIS FACTOR-ALPHA; YOUNG ADULT;

EID: 84908693457     PISSN: 01655728     EISSN: 18728421     Source Type: Journal    
DOI: 10.1016/j.jneuroim.2014.06.013     Document Type: Article

References (39)

1. Attri S., Sharma N., Jahagirdar S., Thapa B.R., Prasad R. Erythrocyte metabolism and antioxidant status of patients with Wilson disease with hemolytic anemia. Pediatr. Res. 2006, 59:593-597.
2. Bruha R., Vitek L., Marecek Z., Pospisilova L., Nevsimalova S., Martasek P., Petrtyl J., Urbanek P., Jiraskova A., Malikova I., Haluzik M., Ferenci P. Decreased serum antioxidant capacity in patients with Wilson disease is associated with neurological symptoms. J. Inherit. Metab. Dis. 2011, 35:541-548.
3. Chen D.B., Feng L., Lin X.P., Zhang W., Li F.R., Liang X.L., Li X.H. Penicillamine increases free copper and enhances oxidative stress in the brain of toxic milk mice. PLoS ONE 2012, 7:e37709.
4. Choi B.S., Zheng W. Copper transport to the brain by the blood-brain barrier and blood-CSF barrier. Brain Res. 2009, 1248:14-21.
5. Crum R.M., Anthony J.C., Bassett S.S., Folstein M.F. Population-based norms for the Mini-Mental State Examination by age and educational level. JAMA 1993, 269:2386-2391.
6. Dalgic B., Sonmez N., Biberoglu G., Hasanoglu A., Erbas D. Evaluation of oxidant stress in Wilson's disease and non-Wilsonian chronic liver disease in childhood. Turk. J. Gastroenterol. 2005, 16:7-11.
7. Drachman D.B., Frank K., Dykes-Hoberg M., Teismann P., Almer G., Przedborski S., Rothstein J.D. Cyclooxygenase 2 inhibition protects motor neurons and prolongs survival in a transgenic mouse model of ALS. Ann. Neurol. 2002, 52:771-778.
8. Dringen R., Bishop G.M., Koeppe M., Dang T.N., Robinson S.R. The pivotal role of astrocytes in the metabolism of iron in the brain. Neurochem. Res. 2007, 32:1884-1890.
9. Fine S.M., Angel R.A., Perry S.W., Epstein L.G., Rothstein J.D., Dewhurst S., Gelbard H.A. Tumor necrosis factor alpha inhibits glutamate uptake by primary human astrocytes. Implications for pathogenesis of HIV-1 dementia. J. Biol. Chem. 1996, 271:15303-15306.
10. Goyal M.K., Sinha S., Patil S.A., Jayalekshmy V., Taly A.B. Do cytokines have any role in Wilson's disease?. Clin. Exp. Immunol. 2008, 154:74-79.
11. Grimm G., Prayer L., Oder W., Ferenci P., Madl C., Knoflach P., Schneider B., Imhof H., Gangl A. Comparison of functional and structural brain disturbances in Wilson's disease. Neurology 1991, 41:272-276.
12. Halliwell B. Role of free radicals in the neurodegenerative diseases: therapeutic implications for antioxidant treatment. Drugs Aging 2001, 18:685-716.
13. Hara H., Friedlander R.M., Gagliardini V., Ayata C., Fink K., Huang Z., Shimizu-Sasamata M., Yuan J., Moskowitz M.A. Inhibition of interleukin 1beta converting enzyme family proteases reduces ischemic and excitotoxic neuronal damage. Proc. Natl. Acad. Sci. U. S. A. 1997, 94:2007-2012.
14. Hensley K., Robinson K.A., Gabbita S.P., Salsman S., Floyd R.A. Reactive oxygen species, cell signaling, and cell injury. Free Radic. Biol. Med. 2000, 28:1456-1462.
15. Huang P.P., Esquenazi S., Le Roux P.D. Cerebral cortical neuron apoptosis after mild excitotoxic injury in vitro: different roles of mesencephalic and cortical astrocytes. Neurosurgery 1999, 45:1413-1422.
16. Janero D.R. Malonodialdehyde and thiobarbituric acid-reactivity as diagnostic indices of lipid peroxidation and peroxidative tissue injury. Free Radic. Biol. Med. 1990, 9:515-540.
17. Kaler S.G. ATP7A-related copper transport diseases-emerging concepts and future trends. Nat. Rev. Neurol. 2011, 7:15-29.
18. Kalita J., Somarajan B.I., Misra U.K., Mittal B. R778L, H1069Q, and I1102T mutation study in neurologic Wilson disease. Neurol. India 2010, 58:627-630.
19. Kalita J., Kumar V., Chandra S., Kumar B., Misra U.K. Worsening of Wilson disease following penicillamine therapy. Eur. Neurol. 2013, 71:126-131.
20. Karin M., Greten F.R. NF-kappaB: linking inflammation and immunity to cancer development and progression. Nat. Rev. Immunol. 2005, 5:749-759.
21. Kodama H., Fujisawa C., Bhadhprasit W. Pathology, clinical features and treatments of congenital copper metabolic disorders-focus on neurologic aspects. Brain Dev. 2010, 33:243-251.
22. Koracevic D., Koracevic G., Djordjevic V., Andrejevic S., Cosic V. Method for the measurement of antioxidant activity in human fluids. J. Clin. Pathol. 2001, 54:356-361.
23. Krystkowiak P., Du Montcel S.T., Vercueil L., Houeto J.L., Lagrange C., Cornu P., Blond S., Benabid A.L., Pollak P., Vidailhet M. Reliability of the Burke-Fahn-Marsden scale in a multicenter trial for dystonia. Mov. Disord. 2007, 22:685-689.
24. Lovell M.A., Ehmann W.D., Butler S.M., Markesbery W.R. Elevated thiobarbituric acid-reactive substances and antioxidant enzyme activity in the brain in Alzheimer's disease. Neurology 1995, 45:1594-1601.
25. Nagasaka H., Inoue I., Inui A., Komatsu H., Sogo T., Murayama K., Murakami T., Yorifuji T., Asayama K., Katayama S., Uemoto S., Kobayashi K., Takayanagi M., Fujisawa T., Tsukahara H. Relationship between oxidative stress and antioxidant systems in the liver of patients with Wilson disease: hepatic manifestation in Wilson disease as a consequence of augmented oxidative stress. Pediatr. Res. 2006, 60:472-477.
26. Ogihara H., Ogihara T., Miki M., Yasuda H., Mino M. Plasma copper and antioxidant status in Wilson's disease. Pediatr. Res. 1995, 37:219-226.
27. Roberts E.A., Schilsky M.L., American Association For Study Of Liver D. Diagnosis and treatment of Wilson disease: an update. Hepatology 2008, 47:2089-2111.
28. Rumack C.M., Wilson S.R., Charboneau J.W., Levine D. Diagnostic ultrasound. Mosby - Year Book 2011, 1. (January 5).
29. Scheiber I.F., Dringen R. Astrocyte functions in the copper homeostasis of the brain. Neurochem. Int. 2012, 62:556-565.
30. Schlief M.L., Gitlin J.D. Copper homeostasis in the CNS: a novel link between the NMDA receptor and copper homeostasis in the hippocampus. Mol. Neurobiol. 2006, 33:81-90.
31. Schosinsky K.H., Lehmann H.P., Beeler M.F. Measurement of ceruloplasmin from its oxidase activity in serum by use of o-dianisidine dihydrochloride. Clin. Chem. 1974, 20:1556-1563.
32. Schulz J.B., Lindenau J., Seyfried J., Dichgans J. Glutathione, oxidative stress and neurodegeneration. Eur. J. Biochem. 2000, 267:4904-4911.
33. Teles M., Mackenzie S., Boltana S., Callol A., Tort L. Gene expression and TNF-alpha secretion profile in rainbow trout macrophages following exposures to copper and bacterial lipopolysaccharide. Fish Shellfish Immunol. 2010, 30:340-346.
34. Thomas G.R., Forbes J.R., Roberts E.A., Walshe J.M., Cox D.W. The Wilson disease gene: spectrum of mutations and their consequences. Nat. Genet. 1995, 9:210-217.
35. Tietze F. Enzymic method for quantitative determination of nanogram amounts of total and oxidized glutathione: applications to mammalian blood and other tissues. Anal. Biochem. 1969, 27:502-522.
36. Turnlund J.R., Jacob R.A., Keen C.L., Strain J.J., Kelley D.S., Domek J.M., Keyes W.R., Ensunsa J.L., Lykkesfeldt J., Coulter J. Long-term high copper intake: effects on indexes of copper status, antioxidant status, and immune function in young men. Am. J. Clin. Nutr. 2004, 79:1037-1044.
37. Vrabelova S., Letocha O., Borsky M., Kozak L. Mutation analysis of the ATP7B gene and genotype/phenotype correlation in 227 patients with Wilson disease. Mol. Genet. Metab. 2005, 86:277-285.
38. Walshe J.M., Yealland M. Wilson's disease: the problem of delayed diagnosis. J. Neurol. Neurosurg. Psychiatry 1992, 55:692-696.
39. Zou J.Y., Crews F.T. TNF alpha potentiates glutamate neurotoxicity by inhibiting glutamate uptake in organotypic brain slice cultures: neuroprotection by NF kappa B inhibition. Brain Res. 2005, 1034:11-24.